<DOC>
	<DOC>NCT01902459</DOC>
	<brief_summary>The objective of this study is to evaluate the clinical utility of EVARREST™ Fibrin Sealant Patch (Fibrin Pad) as an adjunct to hemostasis in soft tissue bleeding during intra-abdominal (stomach area), retroperitoneal (hip and stomach area), pelvic (hip area) and non-cardiac thoracic (chest area) surgery.</brief_summary>
	<brief_title>EVARREST™ Fibrin Sealant Patch Post-Market Study</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Fibrin Tissue Adhesive</mesh_term>
	<criteria>Subjects ≥18 years of age, requiring an elective or urgent, open intraabdominal, retroperitoneal, pelvic or noncardiac thoracic surgical procedures; Subjects or legally authorized representative must be willing to participate in the study and provide written informed consent. Presence of an appropriate Target Bleeding Site as identified intraoperatively by the surgeon; Subjects with known intolerance to blood products or to one of the components of EVARREST™ or unwilling to receive blood products; Female subjects who are pregnant or nursing. TBS is from a large defect in an artery or vein where the injured vascular wall requires repair and maintenance of vessel patency or where there would be persistent exposure of EVARREST™ to blood flow and/or pressure during absorption of the product; TBS with major arterial bleeding requiring suture or mechanical ligation; TBS within a contaminated or infected area of the body; Bleeding site is in, around, or in proximity to foramina in bone, or areas of bony confine; Subjects with any intraoperative findings identified by the surgeon that may preclude conduct of the study procedure;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Hemostasis</keyword>
</DOC>